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BACKGROUND: Dilated cardiomyopathy (DCM) is genetically 
heterogeneous, with >100 purported disease genes tested in clinical 
laboratories. However, many genes were originally identified based on 
candidate-gene studies that did not adequately account for background 
population variation. Here we define the frequency of rare variation in 
2538 patients with DCM across protein-coding regions of 56 commonly 
tested genes and compare this to both 912 confirmed healthy controls 
and a reference population of 60 706 individuals to identify clinically 
interpretable genes robustly associated with dominant monogenic DCM.
METHODS: We used the TruSight Cardio sequencing panel to evaluate 
the burden of rare variants in 56 putative DCM genes in 1040 patients 
with DCM and 912 healthy volunteers processed with identical 
sequencing and bioinformatics pipelines. We further aggregated data 
from 1498 patients with DCM sequenced in diagnostic laboratories 
and the Exome Aggregation Consortium database for replication and 
meta-analysis.
RESULTS: Truncating variants in TTN and DSP were associated with DCM 
in all comparisons. Variants in MYH7, LMNA, BAG3, TNNT2, TNNC1, PLN, 
ACTC1, NEXN, TPM1, and VCL were significantly enriched in specific patient 
subsets, with the last 2 genes potentially contributing primarily to early-
onset forms of DCM. Overall, rare variants in these 12 genes potentially 
explained 17% of cases in the outpatient clinic cohort representing a broad 
range of adult patients with DCM and 26% of cases in the diagnostic 
referral cohort enriched in familial and early-onset DCM. Although the 
absence of a significant excess in other genes cannot preclude a limited role 
in disease, such genes have limited diagnostic value because novel variants 
will be uninterpretable and their diagnostic yield is minimal.
CONCLUSIONS: In the largest sequenced DCM cohort yet described, 
we observe robust disease association with 12 genes, highlighting their 
importance in DCM and translating into high interpretability in diagnostic 
testing. The other genes analyzed here will need to be rigorously evaluated 
in ongoing curation efforts to determine their validity as Mendelian DCM 
genes but have limited value in diagnostic testing in DCM at present. This 
data will contribute to community gene curation efforts and will reduce 
erroneous and inconclusive findings in diagnostic testing.
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Dilated cardiomyopathy (DCM) is an inheritable heart disease affecting up to 1 in 250 individu-als and is characterized by genetic heterogeneity, 
and variable penetrance and expressivity.1 The advent 
of efficient high-throughput sequencing platforms has 
led to a rapid increase in the number of genes in which 
variants have been reported as causative, largely based 
on candidate-gene approaches. The Human Gene Mu-
tation Database collated 68 genes as associated with 
primary DCM between 1996 and 2015, and >100 
genes are now routinely tested in clinical diagnostic 
laboratories, including those implicated in syndromic 
forms.2 Variant interpretation in these genes is a key 
challenge faced by clinicians and geneticists.
However, previous studies often did not adequately 
control for background population variation, especially 
before large reference population datasets were avail-
able. The release of the Exome Aggregation Consor-
tium (ExAC) database showed rare variants to be collec-
tively common in the population—with each individual 
carrying ~54 variants previously reported as pathogen-
ic3—and provides the opportunity to reappraise puta-
tive genetic associations by comparing variant preva-
lence in patient cohorts with the >60 000 individuals 
in ExAC. We recently demonstrated the potential of 
this approach through analysis of genes implicated in 
DCM4 and hypertrophic cardiomyopathy.4,5 However, 
the DCM study was limited by the use of patients re-
ferred for genetic testing, which introduces important 
bias (as testing is particularly recommended for young 
and familial patients, and for clinical subphenotypes 
with specific genetic associations, such as LMNA car-
diomyopathy), by the limited number of cases with 
data for some genes (range, 121–1315 individuals per 
gene), and by the absence of data for recently implicat-
ed genes such as ZBTB176 and BAG3.7 Here we address 
these limitations by providing comprehensive analysis 
of 2538 patients with DCM from 2 distinct cohorts—a 
prospectively ascertained adult outpatient cohort and 
an expanded diagnostic laboratory referral cohort—se-
quenced in up to 56 genes. Notably, our previous work 
encompassed the analysis of 22 140 sequenced pa-
tient-gene pairs, whereas here we analyze 89 463. This 
work represents a critical appraisal of the importance 
of genes implicated in monogenic dominant DCM, and 
a reappraisal of its genetic architecture to aid accurate 
identification of pathogenic variants, minimize ambigu-
ous and erroneous findings, and inform genetic testing 
strategies.
METHODS
All data and analytic methods for this study are available to 
other researchers for purposes of reproducing the results or 




The DCM primary outpatient clinic cohort consisted of 
1040 patients with DCM: 863 recruited to the National 
Institute for Health Research Biobank at the Royal Brompton 
Hospital, London (15 of 863 younger than 18 years) and 
177 to the Singapore Biobank at the National Heart Centre 
Singapore. All patients were prospectively enrolled for 
research purposes and underwent cardiac phenotyping with 
either cardiovascular magnetic resonance (CMR) or trans-
thoracic echocardiography, with DCM diagnosed according 
to standard criteria (described in Notes in the online-only 
Data Supplement).
The primary control cohort was composed of 912 healthy 
controls recruited prospectively via advertisement for the UK 
Digital Heart Project at the Medical Research Council London 
Institute of Medical Sciences and Imperial College London.8 
These individuals had no history of medical illness and negative 
family history for cardiovascular disease, were not taking regu-
lar medication, and did not have evidence of cardiac structural 
or functional impairment on CMR imaging. Primary cases and 
controls underwent identical sequencing and bioinformatics 
data processing on the TruSight Cardio panel9 (details in Notes 
in the online-only Data Supplement). All participants gave 
written informed consent, and the study was approved by the 
relevant regional research ethics committees. Demographic 
Clinical Perspective
What Is New?
• This is the largest genetically characterized cohort 
of patients with dilated cardiomyopathy (DCM) yet 
described, comprising 2538 probands.
• By comparing the burden of rare variation in DCM 
cases with a cohort of healthy controls and refer-
ence population data, we demonstrate that most 
genes implicated in DCM do not have a significant 
enrichment of rare variants in cases, indicating they 
are likely to be, at best, rarely causative.
• By analyzing 2 DCM cohorts with distinctive patient 
profiles, we are able to comprehensively evalu-
ate the genetic basis of DCM and identify variant 
classes that are particularly associated with early 
onset disease.
What Are the Clinical Implications?
• This study identifies the genes and variant classes 
that are most relevant for DCM genetic testing and 
those likely to yield interpretable results.
• Our findings will provide key evidence for cura-
tion efforts such as the ClinGen initiative that will 
define valid disease genes for DCM.
• By restricting analysis to validated and interpre-
table genes and variant classes, we can increase 
the accuracy and reduce the uncertainty associated 
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and clinical characteristics of primary DCM cases and controls 
are provided in Table I in the online-only Data Supplement.
Secondary DCM Cohort From Clinical Genetic 
Testing
The secondary diagnostic referral cohort was composed 
of 1498 patients referred for clinical genetic testing to 
either the Oxford Medical Genetics Laboratory (up to 22 
genes sequenced in 304–498 patients) or the Laboratory of 
Molecular Medicine (up to 45 genes sequenced in 135–939 
patients). A proportion of this cohort has been previously 
reported,4 here supplemented with new data from 183 addi-
tional cases and 10 additional genes (Figure 1 and Table II in 
the online-only Data Supplement). Age at diagnosis was avail-
able for 691 patients, of whom 286 were younger than 18 
years (Figure I in the online-only Data Supplement).
Secondary Reference Population
The ExAC dataset is a collation of whole-exome sequencing 
cohorts reprocessed through the same bioinformatics pipe-
line, numbering 60 706 unrelated individuals. We used ExAC 
as a reference population to define rare variants, and as a 
secondary control dataset, as maximizing cohort dimensions 
is key to assess the overall variation burden in small and highly 
constrained genes. Although not healthy controls per se, the 
ExAC subcohorts are from studies of non-Mendelian diseases 
and population controls that are not expected to be enriched 
for DCM cases, and with precautions, ExAC is therefore a suit-
able control for gene-centric analyses of Mendelian disease.10
Selection of Relevant DCM Genes
Fifty-six genes with ≥1 variant reported as pathogenic for 
DCM between 1996 and 2015 in the Human Gene Mutation 
Database (professional v2015.3) and included on the Illumina 
TruSight Cardio panel9 were selected for inclusion in the anal-
ysis, with 44 also targeted by the clinical panels used at the 
Laboratory of Molecular Medicine and Oxford Medical Genetics 
Laboratory (Table II in the online-only Data Supplement). Of 
note, 22 of these 56 genes were not sequenced in our pre-
viously published diagnostic laboratory cohorts.4 Although 
sequenced in all cohorts, RBM20 was excluded from analysis 
because of suboptimal sequencing coverage in ExAC (Figure 
II in the online-only Data Supplement), which is likely to con-
found rare variant identification.
Burden Testing
The combined frequency of rare variants altering canonical 
transcripts of each gene was calculated in each cohort (tran-
script details in Table II in the online-only Data Supplement). 
Rare is defined by a minor allele frequency <0.0001 in 
ExAC, to allow these data to be directly comparable with 
previous analyses.4,5 Only protein-altering variants were 
compared, with separate calculations for predicted protein-
truncating (nonsense, frameshift, and essential splice site) 
and nontruncating variation (missense and inframe indels). 
In TTN, only variants altering exons constitutively expressed 
in the heart (spliced into >90% of the cardiac transcripts, 
Percent Spliced In>90%)11 were included in our analysis. 
Details of all variants are shown in Tables III, IV, V, VI, and VII 
in the online-only Data Supplement.
A number of steps were taken to ensure we could confi-
dently compare exome sequencing data from ExAC with the 
targeted panel data from the primary cohorts.
First, we controlled for the variable sequencing coverage of 
each gene in ExAC by adjusting to effective population size to 
reflect the proportion of ExAC participants in whom the gene 
was adequately covered (ie, with a PASS filter value, an average 
per-base genotype quality score ≥20 and read depth ≥10×).
Second, we developed an algorithm to calibrate variant-
site quality filters based on the framework recently proposed 
by Guo et al,10 iteratively comparing the prevalence of rare 
synonymous variants—not expected to be disease-related—
between targeted panel data (joint primary DCM and healthy 
control cohorts) and whole-exome sequencing data from 
ExAC with different cut-off combinations. Once the calibra-
tion parameters ensuring equal variant detection in panel 
data and ExAC were detected (ie, no significant burden differ-
ences between panel data and ExAC at the single gene level 
as well as considering all 56 genes together, and genomic 
inflation factor between 0.95 and 1.05), the same cut-offs 
were applied to all subsequent comparisons on protein-alter-
ing variants. Details are provided in the Notes in the online-
only Data Supplement.
Third, because our analysis also includes ExAC as a control 
cohort to maximize statistical power, we compared variant 
burdens in ExAC to those in the healthy control cohort.
The burden of rare protein-altering variants at the single-
gene level in cases and controls was assessed over 3 compari-
sons: primary DCM cases vs healthy controls sequenced on 
the same platform, primary DCM cases vs ExAC, and second-
ary DCM cases vs ExAC (Figure 2).
Because different ethnicities were included, an additional 
sensitivity comparison was performed downstream between 
self-reported white patients with DCM and the Non-Finnish 
European subset of ExAC to demonstrate that results were 
not driven by stratification bias and consistent results are 
observed when assessing all ethnicities and whites only.
Statistical Analysis
Burden comparisons were performed using Fisher’s exact test 
(1-sided for testing enrichment, ie, DCM cases vs healthy 
controls and vs ExAC; and 2-sided for testing differences, ie, 
healthy controls vs ExAC and comparisons of synonymous 
variants burden). All reported P values are corrected with 
the Bonferroni method for testing 56 genes (nominal P*56) 
unless otherwise specified, so a P<0.05 is considered signifi-
cant. Correlation of burden differences in the sensitivity analy-
sis was measured using Pearson’s R coefficient.
Age at diagnosis was compared between genotype-pos-
itive (ie, carriers of ≥1 variant of any variant class enriched 
in DCM) and genotype-negative individuals by means of a 
Wilcoxon rank-sum test, and among the different variant 
classes using a Kruskal-Wallis test.
Etiological Fraction
For each variant class with a significant excess in DCM cohorts, 
we computed the corresponding etiological fraction, a deriva-
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which provides a quantitative measure of the interpretability 
of such variants.4 The etiological fraction estimates the pro-
portion of confirmed cases with rare variants in which the 
disease is attributable to the presence of the rare variant itself. 
In a dominant monogenic inheritance model, this also repre-
sents prior probability that a rare variant is pathogenic, given 
that it is found in a confirmed case.
Statistical Power
Comparing 1040 patients with DCM with 912 healthy con-
trols gives 80% power to detect a burden difference of 1% 
against a background variation rate of 0.36% in controls for 
a single gene tested. Using ExAC as a control cohort (mean 
size = 58 666 individuals sequenced for the genes analyzed) 
increases sensitivity, allowing detection of a 1% difference 
with a background control variation rate ~4-fold higher 
(1.22%). Details on how these calculations were performed 
are provided in the Notes in the online-only Data Supplement.
RESULTS
Technical Quality Control and Suitability 
of ExAC as Control Cohort
As expected, coverage in ExAC (ie, mean percent-
age of sample bases covered at 10×) was significantly 
lower and more variable compared with our targeted 
panel data (ExAC: 88.3±11.3%, panel: 99.8±0.3%, 
P=9.4×10–19; Figure II in the online-only Data Supple-
ment). Controlling for the variable sequencing coverage 
Figure 1. Number of dilated cardiomyopathy (DCM) cases sequenced for each gene and cohort. 
The primary cohort is the outpatient DCM cohort. The secondary clinical genetic testing referral cohort was composed of cases that had been previously reported4 
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and applying the quality control steps outlined in the 
Methods, the frequency of rare (minor allele frequency 
<0.0001) synonymous variants in the 56 genes tested 
was comparable between primary cohorts (n=1040 
DCM + 912 healthy controls) and ExAC across the gene 
set (31.6% in panel data vs 30.3% in ExAC, P=0.25) 
and in single genes (0.65≤P≤1, Figure III and Table VIII 
in the online-only Data Supplement), confirming com-
parability of sequencing data from primary cohorts and 
ExAC in terms of variant detection sensitivity. The corre-
sponding optimal genomic inflation factor for the distri-
bution of the 56 single-gene P values was 1.008 (Figure 
IV in the online-only Data Supplement), ensuring the 
absence of systematic bias.
Applying the derived optimal variant quality cut-offs, 
burden testing of rare protein-altering variants showed 
comparable variant frequencies in the 912 confirmed 
healthy controls and ExAC at the gene-set level (67.7% 
in healthy controls vs 67.8% in ExAC, P=0.94) as well 
as at the single-gene level (0.07<P<1, Figure V and Ta-
ble IX in the online-only Data Supplement), confirming 
the suitability of ExAC as control cohort when appropri-
ate filtering is applied.
Burden of Rare Protein-Altering Variants 
in DCM Compared With Control Cohorts
DCM Primary Outpatient Cohort
Protein-truncating variants in constitutive exons (Percent 
Spliced In>90%) of TTN and in DSP were significantly 
enriched in patients with DCM compared with healthy 
controls (TTN 11.3% DCM vs 0.4% healthy controls, 
P=6.2×10–27; DSP 1.4% vs 0.0%, P=4.2×10–3). We con-
firmed these findings using ExAC as a control cohort, 
and with this increased power were additionally able 
to detect disease associations with truncating variants 
in BAG3 (0.3% DCM vs 0.007% ExAC, P=9.1×10–3) 
and LMNA (0.3% vs 0.007%, P=1.0×10–2), as well 
as nontruncating variants in MYH7 (2.9% vs 1.3%, 
P=4.9×10–3) and TNNT2 (1.3% vs 0.2%, P=2.2×10–6; 
Table; Figure 3; details of single gene burden tests in 
Table IX in the online-only Data Supplement and single 
variants identified in primary cohorts in Tables III and IV 
in the online-only Data Supplement).
DCM Secondary Diagnostic Laboratory Referral 
Cohort
The secondary referral DCM cohort provides an op-
portunity for replication, and also addresses potential 
biases affecting our primary DCM cohort caused by 
the CMR-based recruitment strategy and the under-
representation of pediatric patients. Ten of the ana-
lyzed genes were not sequenced in the secondary co-
hort (ACTA1, DNAJC19, FKTN, NKX2-5, NPPA, SGCB, 
TBX20, TBX5, TMPO, and ZBTB17), and the number of 
cases sequenced per gene ranged from 135 to 1498. 
Comparison of the diagnostic referral cohort with ExAC 
replicated all significant associations observed with the 
primary outpatient cohort and additionally showed 
truncating variants in VCL (0.8% vs 0.03%, P=2.5×10–5) 
and nontruncating variants in TPM1 (1.6% vs 0.07%, 
Figure 2. Overview of the cohorts and rare variant burden analyses performed in this study. 
The primary cohort (n=1040) was compared with 912 healthy controls sequenced on the same platform and with the Exome Aggregation Consortium (ExAC) 
reference dataset. A further 1498 cases were sequenced in diagnostic laboratories on a range of platforms over a decade, and compared with ExAC (n=60 706). 
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P=3.1×10–18), LMNA (1.6% vs 0.4%, P=6.5×10–5), and 
TNNC1 (1.2% vs 0.5%, P=2.7×10–3) to be significantly 
enriched in DCM (Table; Figure 3; details of single gene 
burden tests in Table X in the online-only Data Supple-
ment and single variants identified in the secondary 
DCM cohort in Tables V, VI, and VII in the online-only 
Data Supplement).
In addition, although no significant enrichment was 
observed for either truncating or nontruncating vari-
ants (analyzed separately) in ACTC1, NEXN, and PLN, 
patients with DCM of the secondary diagnostic refer-
ral cohort were significantly enriched for aggregated 
protein-altering variants in these 3 genes (truncating + 
nontruncating; ACTC1 0.47% vs 0.07%, P=1.9×10–2, 
NEXN 2.9% vs 0.7%, P=1.6×10–2, PLN 0.4% vs 0.04%, 
P=2.7×10–2).
We found variants in TPM1 and VCL to occur sig-
nificantly more often than expected in pediatric DCM 
(TPM1: 10 of 12 carriers for whom age of onset was 
known were <18 years of age, FDR-adjusted exact 
binomial test P=2.7×10–2, VCL: 5 of 5 <18 years, 
P=4.3×10–2; details in Notes in the online-only Data 
Supplement).
Integrating Findings Across Cohorts
In summary, DCM was associated with truncating vari-
ants in TTN and DSP in all comparisons. A significant as-
sociation with truncating variants in BAG3 and LMNA, 
and nontruncating variants in MYH7 and TNNT2, was 
demonstrated when comparing each DCM cohort to 
ExAC. The enrichment of truncating variants in VCL, and 
nontruncating variants in TPM1, LMNA, and TNNC1, 
was unique to the diagnostic referral cohort (Table; Fig-
ure 4), as was the case for aggregate truncating and 
nontruncating variation in ACTC1, NEXN, and PLN. The 
total excess burden of rare variants (in these 13 sig-
nificantly enriched variant classes), which provides an 
estimate of “diagnostic yield” for testing these genes, 
was 16.7% (95% CI, 14.2%–19.2%) in the unselected 
primary cohort and 25.9% (95% CI, 23.0%–28.9%) in 
the diagnostic referral cohort.
The total excess burden of rare variation in each 
gene provides an estimate of the eventual diagnostic 
yield that might be achieved with optimum variant in-
terpretation. Of note, TTN accounts for ~11% of DCM 
cases in these cohorts, whereas each other gene con-
tributes ~0.3% to 3% (Figure  4). Detailed results of 
Table. Genes With Significant Rare Variant Enrichment in DCM
Gene
Reference Samples DCM Samples
ExAC
Healthy 





















BAG3 0.01% 0.00% 0.29% 0.28% 9.12E−3 0.98 0.29% 1 1.64% 1.63% 5.33E-5 >0.99
DSP 0.07% 0.00% 1.44% 1.37% 1.55E−12 0.95 1.44% 4.23E−3 1.97% 1.90% 1.17E-11 0.97
LMNA 0.01% 0.00% 0.29% 0.28% 1.02E−2 0.98 0.29% 1 1.14% 1.13% 4.13E-19 >0.99
TTN 0.55% 0.44% 11.35% 10.80% 4.03E−102 0.96 10.91% 6.24E−27 11.66% 11.12% 1.89E-67 0.96
VCL 0.03% 0.00% 0.10% 0.07% 1 … 0.10% 1 0.78% 0.75% 2.52E-5 0.96
Nontruncating variants
LMNA 0.43% 0.22% 0.87% 0.44% 1 … 0.65% 1 1.63% 1.20% 6.49E-5 0.74
MYH7 1.31% 1.21% 2.88% 1.58% 4.89E−3 0.554 1.68% 0.385 4.27% 2.97% 1.68E-13 0.70
TNNC1 0.05% 0.00% 0.29% 0.24% 1 … 0.29% 1 1.18% 1.13% 2.73E-3 0.96
TNNT2 0.16% 0.11% 1.25% 1.09% 2.24E−6 0.88 1.14% 0.107 2.44% 2.28% 1.73E-25 0.94
TPM1 0.07% 0.11% 0.29% 0.22% 1 … 0.18% 1 1.62% 1.55% 3.06E-18 0.96
Protein-altering variants (truncating + nontruncating)
ACTC1 0.07% 0.00% 0.00% −0.07% 1 … 0.00% 1 0.47% 0.40% 1.88E-2 0.86
NEXN 0.74% 0.99% 1.15% 0.41% 1 … 0.17% 1 2.95% 2.21% 1.61E-2 0.75
PLN 0.05% 0.11% 0.00% −0.05% 1 … −0.11% 1 0.39% 0.35% 2.67E-2 0.89
For genes confirmed associated with dilated cardiomyopathy (DCM), the prevalence of truncating and nontruncating variants in patients (primary or secondary 
cohort) is compared with controls (healthy controls or the Exome Aggregation Consortium [ExAC] population reference cohort). P values are from the Fisher exact 
tests as described in the Methods and are adjusted for testing 56 genes with the Bonferroni method (significant if Padjusted<0.05, nonsignificant comparisons shown 
in italics). In TTN, only variants altering exons that are constitutively expressed in the heart (Percent Spliced In>90%) were analyzed. The reported etiological fraction 
(EF; ie, the proportion of confirmed cases with rare variants in which the disease is attributable to the presence of the rare variant itself) for genetic variants in the 
primary DCM cohort was derived comparing cumulative variant frequencies between DCM cases and ExAC, and is not reported whenever this comparison did not 
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all comparisons are provided in Tables IX and X in the 
online-only Data Supplement.
Interpretability of Variant Classes Measured by 
Etiological Fraction
The etiological fraction estimates the prior probability 
that a rare variant of a particular variant class is patho-
genic if found in a patient with disease. As expected, we 
observed truncating variants in the genes with a con-
firmed disease association to have high etiological frac-
tions, reflecting the rarity of such variants in the popu-
lation, whereas etiological fractions for nontruncating 
variants were more modest (eg, 0.99 and 0.74 for trun-
cating and nontruncating variants in LMNA, respec-
tively (Figure 5; Table). In contrast, etiological fractions 
for nonenriched genes were low and nonsignificant 
(Tables IX and X in the online-only Data Supplement), 
indicating that the prior probability that a novel variant 
in these genes is pathogenic is low, and a great deal of 
evidence would be required to assert pathogenicity. Of 
note, the likelihood of pathogenicity for a rare variant 
found in a patient as estimated by etiological fraction 
(interpretability) is distinct from, but not independent 
of, both the probability that it will inform treatment, 
Figure 3. Comparison of the prevalence of rare protein-altering variation between dilated cardiomyopathy (DCM) cases and the Exome Aggrega-
tion Consortium (ExAC) reference dataset. 
Genes with a statistically significant association with disease are highlighted in red. Results are shown separately for truncating and nontruncating variants, and 
for primary and secondary cohorts. Truncating variants in TTN, robustly associated with DCM (prevalence 11.3% in primary DCM cohort and 11.7% in secondary 
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and the potential to predict disease onset in relatives 
(penetrance). For genes like MYH7 or LMNA, known 
pathogenic variants are highly penetrant in families and 
informative for clinical care, despite both genes hav-
ing a relatively low etiological fraction for nontruncat-
ing variants in aggregate, because of substantial levels 
of rare benign variation in the population. In contrast, 
truncating variants in TTN are highly likely to be dis-
ease-causing when found in an individual with DCM 
but have been shown to have reduced penetrance in 
the wider population.
Posterior Quality Control on Ethnicity 
Stratification
The per-gene excess of rare variants in primary patients 
with DCM (N=1040) over the full ExAC dataset and the 
one observed using only samples of European descent 
(white primary DCM cases (N=721) versus the Non-
Finnish European subset of ExAC  (N=33 270) showed 
strong positive correlation (R2 = 0.975, Figure VI in the 
online-only Data Supplement). None of the 44 genes 
not enriched for rare variation in DCM were associ-
ated with the condition in the 721 white patients (P 
values in the range 0.39–1), and the prevalence of the 
13 enriched variant classes was comparable in ExAC vs 
the Non-Finnish European subset of ExAC as well as in 
primary DCM vs primary white patients with DCM (P 
values in the range 0.15–1). In addition, we recently 
showed that population stratification was not a signifi-
cant confounding factor in the subset of the secondary 
clinical DCM cohort included in our previous analysis.4 
These findings suggest that the results of this analysis 
are robust to population stratification.
Genotype in Relation to Age and Family 
History
Age at diagnosis was significantly different between 
genotype-positive and genotype-negative patients 
with DCM (mean±SD, 47.8±16.2 years vs 56.1±14.3 
years, respectively, P=4.5×10–10), but we did not 
detect a significant effect of specific gene/variant 
Figure 4. Case excess of rare variants in genes significantly enriched in dilated cardiomyopathy (DCM). 
The excess burden of rare protein-altering variation (above the population background rate) provides an estimate of the proportion of cases attributable to varia-
tion in each gene under a dominant monogenic inheritance model. Genes with a significant enrichment of rare truncating (A) and nontruncating (B) variants in 
patients with DCM compared with controls are shown (with the exceptions of ACTC1, PLN, and NEXN, where we detected an enrichment of joint truncating and 
nontruncating variation in DCM but not when the 2 variant classes were analyzed separately). Results are summarized for 3 comparisons as shown in Figure 2. 
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classes (P=0.3). Patients with positive family history 
are diagnosed earlier, both within genotype-positives 
(41.5±16.3 years vs 49.1±15.6, P=0.007) and within 
genotype-negatives (50.1±16.3 years vs 56.4±14.1, 
P=0.02), and are characterized by a higher yield of 
potentially pathogenic variants (40.0% vs 17.6%, 
P=1.4×10–6). Full details are provided in Table XI in the 
online-only Data Supplement.
DISCUSSION
In this study, we have compared the burden of rare 
protein-altering variation in DCM-associated genes in 
up to 2538 patients with DCM—to our knowledge the 
largest such study to date—to the background genetic 
variation in both healthy controls and the ExAC refer-
ence population.
We propose that the variant classes significantly en-
riched in 1 or both DCM cohorts are likely to be most 
relevant for genetic testing in DCM. These were trun-
cating variants in TTN, DSP, LMNA, BAG3, and VCL, 
and nontruncating variants in MYH7, TNNT2, TNNC1, 
LMNA, and TPM1 (Table). Analyzing truncating and 
nontruncating variants jointly, variants in ACTC1, NEXN, 
and PLN were also associated with DCM. BAG3 is one 
of the more recently implicated DCM genes and was 
not assessed in our previous study. Here, a significant 
excess of BAG3-truncating (but not nontruncating) 
variants was observed in DCM, consistent with multiple 
reports of the cosegregation of BAG3-truncating alleles 
with DCM in large pedigrees (Table XII in the online-
only Data Supplement).
The analysis of 2 distinct patient cohorts represents 
a strength of the study, as it enables the dissection of 
the genetic basis of DCM in different contexts. Our pri-
mary DCM cohort evaluates the contribution of known 
genetic determinants to DCM across a broad range of 
cases, including less severe, later-onset and nonfamil-
ial cases that are likely underrepresented in cohorts 
selectively referred for diagnostic sequencing, because 
genetic testing has primarily been recommended for 
patients with strong family history and/or conduction 
disease.12 It also enables us to compare data from cases 
and controls with standardized sequencing and uni-
form data processing to minimize technical artefacts. 
However, although CMR evaluation in this cohort pro-
vides accurate deep phenotyping, this may also intro-
duce bias, eg, against infant patients or those with im-
planted cardiac devices. This is likely to impact genes 
associated with pediatric forms of DCM,13 and genes, 
such as LMNA, that are associated with DCM in com-
bination with conduction disease and arrhythmia likely 
to require device implantation. Consistent with this, 
rare LMNA variants were >2.5-fold more frequent in 
the diagnostic referral cohort (2.8%, in line with other 
reported non-CMR cohorts) compared with the CMR-
characterized primary outpatient cohort (1.1%), likely 
reflecting a combination of enrichment in the diag-
nostic referrals (increased likelihood of referral in the 
presence of conduction disease), and depletion in the 
primary cohort (less likely to undergo CMR after device 
therapy).
The genetic determinants of pediatric DCM may be 
distinct from adult-onset DCM,13,14 and our cohorts 
Figure 5. Known and interpretable classes of genetic variants in dilated cardiomyopathy (DCM). 
The case excess (the difference in rare variant prevalence between cases and controls) provides an estimate of the contribution of a gene/variant class to 
DCM (proportion of cases explained by that gene/variant class) and is plotted against the etiological fraction, a measure of the interpretability of rare variants 
detected in patients (the proportion of cases with a variant where that variant is likely causative). Truncating and nontruncating variants are shown separately 




 http://ahajournals.org by on D
ecem
ber 17, 2020
Mazzarotto et al Monogenic Determinants of DCM














differ in their representation of childhood-onset disease 
(primary patient cohort predominantly adult-onset (848 
of 863 [98.3%] older than 18 years); diagnostic referral 
series containing a substantial pediatric population (Fig-
ure I in the online-only Data Supplement, 286 of 691 
[40.4%] patients with age information available young-
er than 18 years). One explanation for associations only 
observed in the diagnostic referral cohort may be a par-
ticular association with early-onset disease. Among vari-
ant classes enriched in the diagnostic referral cohort, we 
found that variants in TPM1 and VCL were significantly 
more prevalent in patients below 18 years of age com-
pared with older patients (P=2.7×10–2 and P=4.3×10–2, 
respectively). This supports previous reports describing 
TPM1 as an important early-onset DCM gene.15,16 Of 
note, protein-altering variants in NEXN and in ACTC1 
were also carried primarily by pediatric patients (NEXN, 
6 of 7 and ACTC1, 5 of 6 carriers), although the preva-
lence was not significantly different in adults vs children 
after correcting for multiple testing.
We observe a considerable difference in diagnostic 
yield between cohorts (16.7% in primary, unselected 
cohort vs 25.9% in secondary diagnostic referral co-
hort), concordant with selective referral for genetic 
testing of patients with clinical features predictive of a 
monogenic etiology, reflecting clinical practice guide-
lines during this period. Some published estimates of 
potential diagnostic yield, including our previous study,4 
focused only on variants with a clinical laboratory clas-
sification of pathogenic or likely pathogenic, which will 
provide a very conservative estimate. The excess of rare 
variants in cases over controls represents what could be 
attainable with improved variant discrimination.
The significant enrichment of rare variation in dis-
ease cases constitutes strong evidence in favor of 
pathogenicity. Forty-four genes analyzed showed no 
excess of rare variation in DCM. Although this does 
not definitively rule out a role in disease, it implies that 
variants in these genes will most likely not be interpre-
table in the diagnostic context, unless strong addition-
al evidence for pathogenicity of the variant in question 
is collected or previously published, and the propor-
tion of cases with monogenic dominant DCM attrib-
utable to these genes will be small. Notably, previous 
work in hypertrophic cardiomyopathy found that most 
genes without a demonstrable excess of rare variation 
in cases had been implicated through candidate-gene 
approaches with limited, if any, statistically robust hu-
man genetic evidence for their involvement in disease,5 
findings recently confirmed by the ClinGen hypertro-
phic cardiomyopathy curation study.17 Similarly, all but 
one of the genes implicated in Brugada syndrome have 
now been refuted by ClinGen curation,18 in concor-
dance with findings from burden testing.19 Examina-
tion of the original reports for selected genes proposed 
as causative for DCM are likely to show that many did 
not fully account for population variation or formally 
test for statistical association, and often did not pro-
vide either robust segregation evidence or convincing 
functional data.
Nonetheless, some of the genes without demonstra-
ble association here may still prove to be causative of 
DCM. Power to demonstrate association will be limited 
for genes causing only a small proportion of DCM (eg, 
evidence of cosegregation of nontruncating variants in 
SCN5A with arrhythmogenic DCM is reported alongside 
functional data demonstrating altered sodium channel 
function20), or for genes in which variation in specific 
functionally important residues or genic subregions is 
disease-associated, but not detectable against back-
ground variation in other regions tolerant of variation. 
For example, the TTN missense variant p.Trp930Arg 
shows convincing cosegregation with DCM,21 support-
ed by functional data,22 yet nontruncating variants in 
TTN are not significantly enriched in any of the compar-
isons we performed (~29%–30% in DCM vs ~27.5% 
in controls), with a very high background variation rate 
in the population. Most missense variation in TTN is 
diagnostically uninterpretable, representing an urgent 
need for strategies to discriminate TTN nontruncating 
variants that contribute to DCM. This demonstrates 
the need for systematic evaluation efforts—such as the 
ClinGen initiative—that review all lines of human ge-
netic evidence alongside functional studies.
These findings will inform genetic testing for DCM, 
both in the composition of test gene panels and the in-
terpretation of results. Restricting clinical testing to genes 
validated for the disease in question, and specific func-
tionally relevant variant classes therein (in combination 
with stringent variant interpretation), is of critical impor-
tance, to avoid false-positive results and a proliferation of 
variants of uncertain significance from large gene panels. 
Both cause significant harm, through anxiety and wasted 
resources. For variant interpretation, etiological fraction 
estimates from case-control studies can be directly use-
ful, estimating the prior probability of pathogenicity for 
different variant types, and determining the level of ad-
ditional evidence required to render a variant actionable 
for family management. These values can also be directly 
incorporated into the variant classification framework as 
we have previously demonstrated,23 leading to a signifi-
cant increase in sensitivity of genetic testing.
Limitations
The TruSight Cardio panel was designed in 2015 and 
does not include genes implicated in DCM more recent-
ly, such as FLNC.24 In addition, RBM20 was excluded 
from analysis because of suboptimal sequencing cov-
erage in ExAC. Convincing evidence for DCM patho-
genicity has been published for specific variants in this 
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what extent novel RBM20 variants are interpretable in 
a diagnostic context.
There are limitations inherent in the use of ExAC as a 
reference population dataset for comparison with a ge-
netic disease like DCM, including imperfect sequencing 
coverage from whole-exome sequencing assays, the un-
known prevalence of DCM among individuals in ExAC, 
and the use of ExAC to define rare variants and as a 
control cohort that could introduce biases. However, our 
sequencing quality control based on presumably benign 
synonymous variants and the adjustment for variable 
sequencing coverage in ExAC enabled calibration of 
burden testing results. This is demonstrated by the com-
parability of ExAC with the 912 confirmed healthy con-
trols over the frequency of rare protein-altering variants, 
the comparable detection rate of synonymous variants 
in ExAC and in our panel sequencing data as well as 
by the unbiased distribution of P values for single-gene 
comparisons of synonymous variants burden (Figures III, 
IV, and V in the online-only Data Supplement).
This evidence cumulatively suggests that ExAC—with 
appropriate quality control—can be reasonably used 
as control population. In our study, these analyses are 
complementary to a well-controlled comparison of uni-
formly sequenced and processed cases and controls. 
Any residual bias arising from comparisons of panel-
sequenced cases with ExAC would be expected to yield 
false-positive associations, rather than false-negative, as 
TruSight Cardio yields more complete target coverage 
and greater sequencing depth than whole-exome se-
quencing in ExAC. As the primary finding of this study is 
that most implicated genes lack any enrichment in cases, 
our results are robust to the most likely direction of bias.
Our analyses in this study focused on variation in pro-
tein-coding regions, as the technology adopted does not 
fully characterize other variant classes such as noncoding, 
epigenetic, and large structural variants, although we 
consider them unlikely to underlie a substantial burden 
of Mendelian disease given the lack of enrichment ob-
served for protein-altering variants in most genes studied 
here. Future studies based on whole-genome sequenc-
ing of patients with DCM will address these issues, and 
eliminate any bias associated with incomplete coverage 
of the coding region in targeted and exome sequencing 
due, for example, to GC-rich regions (ie, sequence re-
gions with high content of guanine and cytosine).27
Survival bias cannot be excluded, so that cohorts may 
be depleted of variants causing severe early-onset DCM, 
and some healthy controls may develop DCM in the 
future. Neither of these potential biases should have a 
large effect on our results: given the prevalence of DCM 
(1 in 250), we would expect <5 healthy controls to po-
tentially develop DCM in the future, and the inclusion of 
the secondary diagnostic laboratory cohort—enriched 
in pediatric patients—allows us to assess early-onset 
DCM in younger patients. Because of consent and data 
privacy issues, we were unable to assess for significant 
differences in characteristics of patients who did not 
agree to participate in this study, but we believe this is 
unlikely to influence generalizability of our findings.
Conclusions
We have comprehensively evaluated rare protein-altering 
variants in genes implicated in DCM in a large cohort, 
and identified 12 genes that have robust evidence of dis-
ease association. We estimated the contribution of these 
genes to disease, which indicates the potential diagnos-
tic yield of sequencing and the prior probability that a 
novel uncharacterized variant identified in an individual 
with disease is pathogenic, and is informative as to clini-
cal interpretability of variation in this gene. These genes 
have clear diagnostic utility in a clinical setting.
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